Methylprednisolone versus dexamethasone for Covid-19 patients: an analysis of a published clinical trial
DOI:
https://doi.org/10.17267/2675-021Xevidence.2021.e3814Downloads
Referências
Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704. https://doi.org/10.1056/nejmoa2021436
Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330-41. https://doi.org/10.1001/jama.2020.17023
National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Coranavírus disease. 2019. Available from: https://www.covid19treatmentguidelines.nih.gov/
Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1):337. https://doi.org/10.1186/s12879-021-06045-3
Moher D, Bouter L, Kleinert S, Glasziou P, Sham MH, Barbour V, et al. The Hong Kong Principles for assessing researchers: Fostering research integrity. PLoS Biol. 2020;18(7):e3000737. https://doi.org/10.1371/journal.pbio.3000737
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2021 Rafael Leite Pacheco, Hugo Mamede, Denusa Wiltgen, Airton Stein
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
The authors retain copyrights, transferring to the Journal of Evidence-Based Healthcare only the right of first publication. This work is licensed under a Creative Commons Attribution 4.0 International License.
